Pharma Deals Review, Vol 2007, No 89 (2007)

Font Size:  Small  Medium  Large

AstraZeneca Gets Verus’ Asthma Assets

Business Review Editor

Abstract


AstraZeneca has taken steps to relieve its current asthma woes by acquiring rights to a pediatric asthma development program from Verus Pharmaceuticals in a deal worth as much as US$310 M to Verus.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.